PGEN
Precigen, Inc. Common Stock
stockNASDAQ
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.94 | 2026-10-30 | -35.81% | 2.905 |
| 1M | 7.54 | 2026-10-07 | -40.91% | 2.584 |
| 3M | 7.23 | 2026-08-07 | -38.38% | 1.836 |
| 6M | 4.15 | 2026-05-07 | +7.35% | 1.908 |
| 1Y | 3.90 | 2025-11-07 | +14.23% | 1.578 |
| 2Y | 0.95 | 2024-11-07 | +368.26% | — |
| 5Y | 4.96 | 2021-11-08 | -10.18% | 1.781 |
Precigen, Inc. Common Stock (NASDAQ:PGEN) stock price today is $4.46, and today's volume is 9,238,336. The 30 day average volume is 6.82M. PGEN market cap is $1.60B with 358.55M shares outstanding.